Literature DB >> 15379892

Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord.

Nicolas Chartrel1, Jérôme Leprince, Cynthia Dujardin, David Chatenet, Hélène Tollemer, Marc Baroncini, Richard J Balment, Jean-Claude Beauvillain, Hubert Vaudry.   

Abstract

The human urotensin II (UII) precursor encompasses several potential cleavage sites and thus, processing of pro-UII may generate various forms of mature UII including the peptides of 11 (UII11), 16 (UII16) and 19 (UII19) residues. Until now, the native form of human UII had not been characterized. Here, we show that the major UII peptide occurring in the human spinal cord corresponds to UII11. In contrast, neither the UII16 nor the UII19 forms could be detected. In 50% of the brainstem and in all the spinal cord extracts analysed, a second minor UII-immunoreactive peptide was resolved. Immunohistochemical labelling of the cervical segment of the human spinal cord revealed that the UII-immunoreactive material was confined to a subset of ventral horn motoneurones. These data provide the first evidence that in the human, the UII precursor, expressed in motoneurones, is processed at the tribasic KKR93 cleavage site to generate a mature form of UII of 11 amino acids. The absence of N-terminally elongated forms of UII of 16 and 19 residues indicates that pro-UII is not cleaved at the R85 or K88 monobasic sites. Finally, the minor UII-immunoreactive peptide detected in several tissue extracts might correspond to an extended form of UII resulting from the processing of the UII precursor at the basic RK50 or RK66 doublets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379892     DOI: 10.1111/j.1471-4159.2004.02698.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

2.  Behavioral effects of urotensin-II centrally administered in mice.

Authors:  Jean-Claude Do-Rego; David Chatenet; Marie-Hélène Orta; Bertrand Naudin; Camille Le Cudennec; Jérôme Leprince; Elizabeth Scalbert; Hubert Vaudry; Jean Costentin
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

3.  State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.

Authors:  Eugen Brailoiu; Xiaohua Jiang; G Cristina Brailoiu; Jun Yang; Jaw Kang Chang; Hong Wang; Nae J Dun
Journal:  Peptides       Date:  2008-01-31       Impact factor: 3.750

4.  Urotensin II in invertebrates: from structure to function in Aplysia californica.

Authors:  Elena V Romanova; Kosei Sasaki; Vera Alexeeva; Ferdinand S Vilim; Jian Jing; Timothy A Richmond; Klaudiusz R Weiss; Jonathan V Sweedler
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.